The eagerly anticipated US Farm Bill has been passed by the House and Senate and is expected to be signed by Trump and passed into law in the next week. The new legislation will allow farmers to access banking services and crop insurance and is expected to signal a wave of investment.


CBD products containing less than 0.3% THC will be removed from Schedule 1 of the Controlled Substances Act, making it legal to cross state lines with revenue predictions of US$2.3 billion by 2022.


With such monumental changes on the horizon in the US, other governments are likely to enact similar changes to industrial hemp in the coming year.


Read more here


The European Monitoring Centre for Drugs and Drug Addiction has released a question and answer guide for policy making in relation to medical cannabis and cannabinoids products.

The document highlights how the classification of cannabis as a ‘drug without any medical uses’ for most of the 20th century has negatively impacted the ability to conduct clinical research worldwide. Targeting policymakers and regulators primarily, the guide gives an overview of clinical and regulatory issues that arise when making cannabis and cannabinoid medicine available as a treatment to a wide variety of illnesses.

For practitioners, patients and the general public, part 1 of the guide answers questions surrounding how the efficacy of medicinal products is assessed and what current evidence is available for cannabis preparations and indications. For those already immersed in the medicalization of the cannabis industry, a profile of novel approaches used in the US, Canada, and Israel provide insights into what the European market can expect, improve upon or modify for their local needs.


“National regulatory frameworks are also complicated and there may sometimes be a lack of clarity regarding both the details of the various approaches and how they operate in practice.”


The document released last week outlines the kinds of evidence required by pharmaceutical regulators to approve medicines for clinical use in the EU. By concisely clarifying many of the confounding factors relating to enacting regulatory frameworks on an international, EU and local basis, European and other high-income countries can utilize this as a resource in the evolution of medical cannabis policymaking.

Find the EMCDDA publication here


Following Mexico’s legalization of medical cannabis in mid-2017 the country is now on a path to nationwide legalization of recreational use. This step will make Mexico the world’s third country to fully legalize cannabis, following Uruguay and Canada.

Earlier in the month, a bill was proposed to fully legalize the plant, creating the Mexican Institute of Regulation and Control of Cannabis. This body will regulate the industrial, medical and recreation markets. New laws will allow any person to carry 30g and produce as many as 20 plants, or 480g per year in home cultivation.

The bill was brought forward by the government elect’s interior minister. It is predicted laws will pass through Congress smoothly and be enacted by mid-2019. These regulations continue LATAM’s movement towards regulated cannabis, with Mexico, Argentina, Chile, Colombia, Peru, all having cannabis regulation policies

Read more here


Israel’s CannaLean has completed in vivo animal studies showing its proprietary formulation lowers blood lipids and thus cholesterol. High cholesterol is associated with cardiovascular disease, one of the leading causes of death globally.

The need for safe and clinically validated medications to treat high cholesterol is vast. Approximately 50% of the world’s adult population is affected by some kind of imbalance in blood lipids, high levels of LDL (the Low Density Lipoprotein that carries cholesterols through the bloodstream) cause a hardening and narrowing of arteries which can lead to heart attack or stroke.

Life-changes and conventional pharmaceuticals often aren’t enough to enact the biochemical changes necessary to bring cholesterol levels into a healthy range. Statins are currently the first line of treatment, such drugs may cause side effects including; muscle pain, gastrointestinal distress and can in the long term effects on blood glucose control and liver function.

CannaLeans novel formulation of CBD and Chitosan (a polysaccharide derived from the skeleton of shellfish) has shown to reduce cholesterol levels in recent preclinical trials.

Read more about this promising new therapy.


Foreign cannabis firms have called on local authorities to legalise the medicinal use of the drug in Hong Kong. But the authorities and experts rubbished the idea, saying there was no market in the city for the drug, even for medicinal use.

Two hundred entrepreneurs took part in the Cannabis Investor Symposium at the W Hotel in West Kowloon last week. They were hoping to get Hongkongers to discuss and invest in overseas cannabis businesses. Two weeks ago, Canada legalised the recreational use of cannabis.


TAIPEI — Several Asian countries are considering steps to decriminalize medical cannabis, potentially putting the region on course to becoming the world’s main production hub of the drug.

A proposal to revise the legal framework in Thailand was submitted last month to Prime Minister Prayuth Chan-ocha, who has supported the plan. This makes it possible for medical cannabis legislation to be enacted by the end of the year.


Its been a busy few weeks in marijuana land.

Canada legalised recreational marijuana, a researcher torpedoed confidence calling the North American market “non-investment grade”, the UK did an about-face and one of the world’s biggest pot stocks joined the New York Stock Exchange.

Meanwhile in Australia the ASX cannabis sector is looking perky.

The spur seems to be the CannaTech conference that starts in Sydney on Sunday — where attendees get “bonus points for creative attire”.


About seven people a day are being approved for medicinal cannabis as new research suggests the $18 million industry could be worth billions within a decade.

Access to the drug is still severely restricted two years after its medicinal use was legalised nationally but a new online application system has increased approvals in recent months.

The Therapeutic Goods Administration approved 469 applications for the drug under the Special Access Scheme between August and September.

That’s up from just 97 between January and February.


Despite “strong” stigma locally, opportunities are aplenty for founders wanting to take advantage of the fast-growing cannabis market according to Australian entrepreneur and industry expert Saul Kaye.

But if startups want to see success, they’ll need to look beyond the “low-hanging fruit” and devise a way to best integrate their existing expertise into the market, rather than diving into something they have no experience in.


Global cannabis firms have rolled into Hong Kong with their own investor forum and called on local authorities to legalise the medicinal use of the drug.


Hong Kong is poised to become the marijuana investment capital of Asia, according to executives at the city’s first ever cannabis investor symposium on Thursday.

The CannaTech cannabis investor forum, held at the five-star W Hotel in Tsim Sha Tsui, aimed at showcasing global investment opportunities in markets where the substance is legal.


The cannabis investor conference in Hong Kong this week started with some stern warnings against smoking pot in the city, which can land you in prison. Then folks got down to talking business.

The Hong Kong Cannabis Investor Symposium on Thursday drew executives from some of the world’s hottest cannabis firms together with more than 200 attendees to talk about the plant’s misconceptions and its investment opportunities. Pot stocks have returned 73 percent in the last 12 months, outpacing Bitcoin, gold and any major equity index. And, despite the prohibition in Hong Kong, many of the forum’s participants said they see attitudes in Asia changing.


The majority of Aussie pot stocks have started making money, with just six turning in nil receipts in the September quarter.

Of the 28 ASX-listed companies with an active interest in the medical cannabis field, there are 19 with business operations largely based (or promoted as based) around marijuana.

Of those, 13 turned in ‘customer receipts’, a record of how much money they received from customers in a quarter.


International hashish corporations have rolled into Hong Kong with their very own investor discussion board and known as on native authorities to legalise the medicinal use of the drug.

However the authorities and consultants shortly extinguished the thought, saying there was no market within the metropolis for the drug, even for medicinal use.

The Hashish Investor Symposium was held on the W Resort in West Kowloon on Thursday, with tickets costing US$1,000 every. It got here two weeks after Canada legalised the leisure use of hashish, and attracted 200 pot entrepreneurs to debate the opportunity of joint enterprises in markets the place the usage of hashish was authorized.

Close Menu